124 related articles for article (PubMed ID: 17512794)
1. Sleep improvement in an insomniac patient with global pituitary insufficiency after change from triple to quadruple cortisol replacement therapy.
Voss U; Tuin I; Krakow K
Sleep Med; 2007 Aug; 8(5):517-9. PubMed ID: 17512794
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency.
García-Borreguero D; Wehr TA; Larrosa O; Granizo JJ; Hardwick D; Chrousos GP; Friedman TC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4201-6. PubMed ID: 11095454
[TBL] [Abstract][Full Text] [Related]
3. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study.
Harbeck B; Kropp P; Mönig H
Appl Psychophysiol Biofeedback; 2009 Jun; 34(2):113-9. PubMed ID: 19387826
[TBL] [Abstract][Full Text] [Related]
4. Acute cortisol administration increases sleep depth and growth hormone release in patients with major depression.
Schmid DA; Brunner H; Lauer CJ; Uhr M; Yassouridis A; Holsboer F; Friess E
J Psychiatr Res; 2008 Oct; 42(12):991-9. PubMed ID: 18226817
[TBL] [Abstract][Full Text] [Related]
5. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
[TBL] [Abstract][Full Text] [Related]
6. Doses and steroids to be used in primary and central hypoadrenalism.
Debono M; Ross RJ
Ann Endocrinol (Paris); 2007 Sep; 68(4):265-7. PubMed ID: 17651687
[TBL] [Abstract][Full Text] [Related]
7. Dex/CRH-test response and sleep in depressed patients and healthy controls with and without vulnerability for affective disorders.
Friess E; Schmid D; Modell S; Brunner H; Lauer CJ; Holsboer F; Ising M
J Psychiatr Res; 2008 Oct; 42(14):1154-62. PubMed ID: 18281062
[TBL] [Abstract][Full Text] [Related]
8. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
Oksnes M; Björnsdottir S; Isaksson M; Methlie P; Carlsen S; Nilsen RM; Broman JE; Triebner K; Kämpe O; Hulting AL; Bensing S; Husebye ES; Løvås K
J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
[TBL] [Abstract][Full Text] [Related]
9. [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia].
Schneider-Helmert D; Hermann E; Schoenenberger GA
Dtsch Med Wochenschr; 1987 Jun; 112(23):922-5. PubMed ID: 3582201
[TBL] [Abstract][Full Text] [Related]
10. Novel strategies for hydrocortisone replacement.
Debono M; Price JN; Ross RJ
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):221-32. PubMed ID: 19500765
[TBL] [Abstract][Full Text] [Related]
11. MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition.
Gyongyosi N; Balogh B; Kirilly E; Kitka T; Kantor S; Bagdy G
Brain Res; 2008 Sep; 1231():34-46. PubMed ID: 18638459
[TBL] [Abstract][Full Text] [Related]
12. Aging-related sleep changes.
Espiritu JR
Clin Geriatr Med; 2008 Feb; 24(1):1-14, v. PubMed ID: 18035227
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
Gagliardi L; Nenke MA; Thynne TR; von der Borch J; Rankin WA; Henley DE; Sorbello J; Inder WJ; Torpy DJ
J Clin Endocrinol Metab; 2014 Nov; 99(11):4149-57. PubMed ID: 25127090
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
Walsh JK; Mayleben D; Guico-Pabia C; Vandormael K; Martinez R; Deacon S
Sleep Med; 2008 May; 9(4):393-402. PubMed ID: 17765013
[TBL] [Abstract][Full Text] [Related]
15. Partial sleep deprivation: impact on the architecture and quality of sleep.
Elmenhorst EM; Elmenhorst D; Luks N; Maass H; Vejvoda M; Samel A
Sleep Med; 2008 Dec; 9(8):840-50. PubMed ID: 17921066
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
Wade AG; Ford I; Crawford G; McMahon AD; Nir T; Laudon M; Zisapel N
Curr Med Res Opin; 2007 Oct; 23(10):2597-605. PubMed ID: 17875243
[TBL] [Abstract][Full Text] [Related]
17. The cortisol awakening response: a pilot study on the effects of shift work, morningness and sleep duration.
Griefahn B; Robens S
Psychoneuroendocrinology; 2008 Aug; 33(7):981-8. PubMed ID: 18650024
[TBL] [Abstract][Full Text] [Related]
18. What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?
Debono M; Ross RJ
Clin Endocrinol (Oxf); 2013 May; 78(5):659-64. PubMed ID: 23194144
[TBL] [Abstract][Full Text] [Related]
19. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy.
Debono M; Ross RJ; Newell-Price J
Eur J Endocrinol; 2009 May; 160(5):719-29. PubMed ID: 19168600
[TBL] [Abstract][Full Text] [Related]
20. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
